Longitudinal FEV<sub>1</sub> and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling.

Zhudenkov, Kirill; Palmér, Robert; Jauhiainen, Alexandra; Helmlinger, Gabriel; Stepanov, Oleg; Peskov, Kirill; Eriksson, Ulf G; Wählby Hamrén, Ulrika

Longitudinal FEV₁ and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling.

Zhudenkov, Kirill; Palmér, Robert; Jauhiainen, Alexandra; Helmlinger, Gabriel; Stepanov, Oleg; Peskov, Kirill; Eriksson, Ulf G; Wählby Hamrén, Ulrika.

Affiliation

Zhudenkov K; M&S Decisions LLC, Moscow, Russia.
Palmér R; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Jauhiainen A; BioPharma Early Biometrics and Statistical Innovation, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Helmlinger G; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Boston, MA, USA.
Stepanov O; Clinical Pharmacology, Toxicology, Quantitative Sciences, Obsidian Therapeutics, Cambridge, MA, USA.
Peskov K; M&S Decisions LLC, Moscow, Russia.
Eriksson UG; M&S Decisions LLC, Moscow, Russia.
Wählby Hamrén U; I.M. Sechenov First Moscow State Medical University of the Russian Ministry of Health, Moscow, Russia.

Int J Chron Obstruct Pulmon Dis ; 16: 101-111, 2021.

Article in En | MEDLINE | ID: mdl-33488073

Subject(s)
Key words

anti-inflammatory; bronchodilator; lung function

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Int J Chron Obstruct Pulmon Dis Year: 2021 Document type: Article Affiliation country: Rusia

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google